Companies · Pharmaceuticals

Apicore Inc.

SOMERSET · Pharmaceuticals

Diligence memoA one-page analyst read on Apicore Inc. — recommendation, valuation, rhythm, risks.
$16.7M
Total raised · real
3
Rounds
0.1×
Latest step-up
Top 38%
Sector rank · raised
Series A
Latest stage · inferred · Mon Sep 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Apicore Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.13× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Apicore Inc. is one of 1610 Pharmaceuticals companies tracked from SOMERSET. By capital raised it ranks mid-pack (ahead of 63% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2014
Year incorporated
2016-09-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2014-07-03 Raised $6.8M (real) Modeled valuation $211M (est)$6.8M$211MSeries A2014Series A · 2014-07-03 Raised $9.2M (real) Modeled valuation $285M (est)$9.2M$285MSeries A2014Series A · 2016-09-26 Raised $720K (real) Modeled valuation $22M (est)$720K$22MSeries A2016+$9.2M+$720KCumulative $17M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.8M · 2014
Series A extension$9.2M · 2014
Series A extension$720K · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$22.3M
Base estimate est.
$825K
Conservative case
$121.3M
Upside case
$3.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $211.4M · 2014-07-032014Series A · modeled $284.9M · 2014-07-03Series A · modeled $22.3M · 2016-09-262016
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
9.8 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$7.5M/yr
Capital velocity
12.0 yr
On record since
2014
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.1× above median
This company$16.7M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$720K
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$22.3M
Sector median$76.1M

Raised more than 63% of sector peers (real $). Modeled value above 29% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #81 of 88.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Arbutus Biopharma Corp · Series A Raised $15.0M · modeled $464.6M (est)Rvc 360, Llc · Series A Raised $15.0M · modeled $464.6M (est)Sterrx, Llc · Series A Raised $18.0M · modeled $464.6M (est)Ribometrix, Inc. · Series A Raised $18.5M · modeled $464.6M (est)Neuraltus Pharmaceuticals, Inc. · Series A Raised $40.6M · modeled $462.7M (est)SiteOne Therapeutics, Inc. · Series A Raised $16.1M · modeled $460.3M (est)Right Value Drug Stores, Inc. · Series A Raised $13.3M · modeled $411.9M (est)USWM Enterprises, LLC · Series A Raised $12.2M · modeled $376.7M (est)Satsuma Pharmaceuticals, Inc. · Series A Raised $12.1M · modeled $375.8M (est)Chase Pharmaceuticals Corp · Series A Raised $26.5M · modeled $370.9M (est)Vitruvias Therapeutics, Inc. · Series A Raised $12.4M · modeled $356.2M (est)Vyome Therapeutics Inc. · Series A Raised $14.5M · modeled $351.1M (est)Apicore Inc. (this company) Raised $16.7M · modeled $22.3M (est)Apicore Inc.
CompanyStageRaised · realValue · estvs peer med.
Arbutus Biopharma CorpSeries A$15.0M$464.6M2.61×
Rvc 360, LlcSeries A$15.0M$464.6M2.61×
Sterrx, LlcSeries A$18.0M$464.6M2.61×
Ribometrix, Inc.Series A$18.5M$464.6M2.61×
Neuraltus Pharmaceuticals, Inc.Series A$40.6M$462.7M2.60×
SiteOne Therapeutics, Inc.Series A$16.1M$460.3M2.59×
Right Value Drug Stores, Inc.Series A$13.3M$411.9M2.31×
USWM Enterprises, LLCSeries A$12.2M$376.7M2.12×
Satsuma Pharmaceuticals, Inc.Series A$12.1M$375.8M2.11×
Chase Pharmaceuticals CorpSeries A$26.5M$370.9M2.08×
Vitruvias Therapeutics, Inc.Series A$12.4M$356.2M2.00×
Vyome Therapeutics Inc.Series A$14.5M$351.1M1.97×
Apicore Inc. this companySeries A$16.7M$22.3M0.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.8M2014-07-03$31.0M$211.4M85%
Series A$9.2M2014-07-03$41.8M$284.9M85%
Series A$720K2016-09-26$3.3M$22.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.8M2014-07-03
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series A$9.2M2014-07-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× larger than the prior — scaling up.
    • 2 investors on this round.
  3. Series A$720K2016-09-26
    • Raised again after 27 mo — slower than the ~13 mo sector norm.
    • Round 12.8× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
2017 ~Q4
Modeled next raise · ~13mo cadence
$720K
Modeled next size est.range $720K$1.2M
0.1×
Last step-up
$7.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Gale4 other2014-07
Todd Sone3 other2014-07
Ravishanker Kovi1 other2014-07
Albert Friesen2014-07
Theron E. Odlaug2016-09
Timothy B. Sawyer2016-09
Vithal Dahduk2016-09
Vithal Dhaduk2014-07
Registry & provenance

Apicore Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1613021
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Igi Laboratories, IncPharmaceuticalsSeries A$16.1M$61.9Mnetwork1 shared operator · same sector · same stage
Ascendia Pharmaceuticals, Inc.PharmaceuticalsSeries A$12.5M$8.6Mnetwork1 shared operator · same sector · same stage
Clene Inc.PharmaceuticalsSeries A$16.6M$33.6Msame sector · same stage
Cero Therapeutics Holdings, Inc.PharmaceuticalsSeries A$16.4M$17.9Msame sector · same stage
Pleopharma, Inc.PharmaceuticalsSeries A$17.4M$20.4Msame sector · same stage
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$17.5M$31.4Msame sector · same stage
Arbor Pharmaceuticals IncPharmaceuticalsSeries B$22.0M$592.2Mnetwork1 shared operator · same sector
Cancer Prevention Pharmaceuticals, Inc.PharmaceuticalsSeries A$18.0M$9.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Apiam Solutions LLCPharmaceuticalsPre-Seed$9.5M82%
PolyCore Therapeutics, Inc.BiotechnologySeries A$78.1M82%
Agile Sciences, IncPharmaceuticalsSeed$38.0M81%
Corerx IncPharmaceuticalsSeries A$92.9M80%
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$31.4M79%
Coeptis Pharmaceuticals, Inc.PharmaceuticalsSeries B$16.4M79%
Macrotope, Inc.PharmaceuticalsPre-Seed$1.1M79%
Cannabinoid API Solutions, LLCPharmaceuticalsSeed$27.4M78%
Frequently asked
How much funding has Apicore Inc. raised?
Apicore Inc. has raised approximately $16.7M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Apicore Inc.'s estimated valuation?
Provath's modeled valuation for Apicore Inc. is approximately $22.3M (modeled range $825K–$121.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Apicore Inc. at?
Apicore Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Sep 26.
What does Apicore Inc. do and where is it based?
Apicore Inc. operates in the Pharmaceuticals sector, based in SOMERSET.
Explore related

See where Apicore Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Apicore Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.